Acclaim-2 – Genprex

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

August 22, 2023Kalyn Dabbs Press Releases

Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer

Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

July 5, 2023Kalyn Dabbs Acclaim 1 Press Releases

Provides Additional Protection in Large Markets for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Keytruda® to Treat Non-Small Cell Lung Cancer

March 31, 2022Kalyn Dabbs Acclaim 2 Press Releases

Company Has FDA Fast Track Designation for Combination of REQORSA and Keytruda

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

May 4, 2021Kalyn Dabbs Acclaim 2 Press Releases

Acclaim-2 Clinical Trial Combines REQORSA™ immunogene therapy with Merck & Co’s Keytruda®